Posted on 06/14/2021 8:36:56 AM PDT by SeekAndFind
Novavax (NASDAQ:NVAX) shares rose more than 6% in Monday’s premarket trading after the company said a phase-three trial had found its two-dose COVID-19 vaccine to be 90.4% effective.
The trial had 29,960 participants across the U.S. and Mexico.
The vaccine was found to be 100% effective in preventing moderate and severe infections and 93% effective against some variants, Novavax said. The company plans to file for approval with the Food and Drug Administration in the third quarter.
Upon regulatory approvals, Novavax remains on track to reach manufacturing capacity of 100 million doses per month by the end of the third quarter and 150 million doses per month by the end of the fourth quarter of 2021, the company said in a release.
Once authorized, the Novavax vaccine would join Pfizer BioNTech (NYSE:PFE) (NASDAQ:BNTX), Moderna (NASDAQ:MRNA) and Johnson&Johnson (NYSE:JNJ), the three COVID-19 shots already approved for emergency use in the U.S.
Barring J&J’s, all are two-dose vaccines.
(Excerpt) Read more at finance.yahoo.com ...
MORE HERE:
While more than half of the U.S. population has had at least one COVID-19 vaccine dose, less than 1 percent of people in the developing world have had one shot, according to Our World In Data.
Novavax’s study involved nearly 30,000 people ages 18 and up in the U.S. and Mexico. Two-thirds received two doses of the vaccine, three weeks apart, and the rest got dummy shots.
There were 77 cases of COVID-19 - 14 in the group that got the vaccine and the rest were in volunteers who received dummy shots. None in the vaccine group had moderate or severe disease, compared to 14 in the placebo group.
The vaccine was similarly effective against several variants including the one first detected in the U.K. that’s dominant in the U.S., and in high-risk populations including the elderly and people with other health problems.
Side effects were mostly mild - tenderness and pain at the injection site. There were no reports of unusual blood clots or heart problems, Erck said.
Novavax reported the results in a press release and plans to publish them in a medical journal, where it will be vetted by independent experts. The Maryland-based company previously released findings from smaller studies in Britain and South Africa.
Right, get that shot of the artificial Spike Protein, it will do you so much good!
Early yet on Side Effects, wait and see what happens.
Copies that came where, well from China.
As opposed to letting the virus come replicate in your body 100 billion times?
Either the S protein is bad and having a minuscule amount of it that doesn’t self-replicate is better than having a huge amount of it self-replicating through your body, or the whole thing is harmless and the vaccine is fine. Can’t have it both ways, where hundreds of billions of virions covered in spike proteins is harmless, but a tiny number of VLPs with spike proteins is the end of humanity.
SOURCE: https://www.nytimes.com/2021/06/14/health/covid-vaccine-novavax.html
Despite these impressive results, the vaccine’s future in the United States is uncertain and it might be needed more in other countries. Novavax says it may not seek emergency authorization from the Food and Drug Administration until the end of September. And with a plentiful supply of three other authorized vaccines, it’s possible that the agency may tell Novavax to apply instead for a full license — a process that could require several extra months.
The company’s chief executive, Stanley Erck, acknowledged in an interview that Novavax would probably win its first authorization elsewhere. The company is also applying in Britain, the European Union, India and South Korea.
“I think the good news is that the data are so compelling that it gives everybody an incentive to pay attention to our filings,” Mr. Erck said.
By the time Novavax gets the green light from the U.S. government, it may be too late to contribute to the country’s first wave of vaccinations. But many vaccine experts expect that, with waning immunity and emerging variants, the country will need booster shots at some point. And the protein-based technology used in the Novavax vaccine may do a particularly good job at amplifying protection, even if people have previously been vaccinated with a different formulation.
The virus itself came from China. The nucleotide sequence that encodes the S protein has been seen around the world. Nobody’s just taking China’s word on any of this. And nobody should; they’re proven liars.
That sounds similar to the new cancer treatments coming on line.
Lol. Watch the stock price spike. Watch the company execs sell off all their stock. Watch the inevitable evidence that exposes that the “vaccine” is not nearly as effective. Watch the stock price plummet.
I’ve seen this movie before.
You take it then.
Since recovery rate is 99.7% WITHOUT a jab, how can you ascertain if the jab works?
You are clueless. The Spike Protein is the most dangerous part and we are putting that in our bodies and it is beyond control and not operating as theorized.
I already had the Moderna vaccine back in February. I’m still waiting on my unicorn horn, my magnetic arms, and my superpowers. Maybe I just need to let the microchips finish connecting to the 5G towers so the aliens can activate them.
Either way, I’m doing just fine. Novavax is great because they provide another option for people who are pro-life but aren’t comfortable taking an mRNA vaccine yet. I think people should have lots of options available. That’s a healthy marketplace.
Since I’ve already had “God’s vaccine”, I don’t need this one. But if I were to take any of them, this one sounds the best.
Would you rather have a small number of spike proteins that can’t replicate or hundreds of billions of self-replicating virions covered in them?
Is COVID-19 a big deal because of the spike proteins? Or is COVID-19 not a big deal because the spike proteins aren’t a big deal? Let’s try for some consistency of thought here.
In addition, if the test subjects felt sick after the second shot and went home and took Advil while the placebo group went to the bars, that could impact the 14 vs 63 split. The placebo should have some nasty additives that also sideline that lot.
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.